Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies

Seminars in Immunology

Volumn 28, Issue 3, 2016, Pages 309-316

  Taylor, Ronald P ^a   Lindorfer, Margaret A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Complement; Immunotherapy of Cancer; Monoclonal antibodies

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; TUMOR ANTIGEN;

ANTIGEN BINDING; CANCER CELL; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; REVIEW; SURVIVAL; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CYTOTOXICITY; GENETIC ENGINEERING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84961219433     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.03.003     Document Type: Review

References (117)

1. [1] Zipfel, P.F., Skerka, C., Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9 (2009), 729–740.
2. [2] Dunkelberger, J.R., Song, W.C., Complement and its role in innate and adaptive immune responses. Cell Res. 20 (2010), 34–50.
3. [3] Carroll, M.C., Isenman, D.E., Regulation of humoral immunity by complement. Immunity 37 (2012), 199–207.
4. [4] Bajic, G., et al. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 34 (2015), 2735–2757.
5. [5] Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190 (2013), 3831–3838.
6. [6] Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190 (2013), 3839–3847.
7. [7] Risitano, A.M., Current and future pharmacologic complement inhibitors. Hematol. Oncol. Clin. North Am. 29 (2015), 561–582.
8. [8] Morgan, B.P., Harris, C.L., Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14 (2015), 857–877.
9. [9] Gancz, D., Fishelson, Z., Cancer resistance to complement-dependent cytotoxicity: Problem-oriented research and development. Mol. Immunol. 46 (2009), 2794–2800.
10. [10] Kolev, M., Towner, L., Donev, R., Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. 59 (2011), 407–419.
11. [11] Golay, J., Introna, M., Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch. Biochem. Biophys. 526 (2012), 146–153.
12. [12] Okroj, M., Osterborg, A., Blom, A.M., Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat. Rev. 39 (2013), 632–639.
13. [13] Meyer, S., Leusen, J.H.W., Boross, P., Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. mAbs 6 (2014), 1133–1144.
14. [14] Derer, S., et al. Complement in antibody-based tumor therapy. Crit. Rev. Immunol. 34 (2014), 199–214.
15. [15] Rogers, L.M., Veeramani, S., Weiner, G.J., Complement in monoclonal antibody therapy of cancer. Immunol. Res. 59 (2014), 203–210.
16. [16] Taylor, R.P., Lindorfer, M.A., The role of complement in mAb-based therapies of cancer. Methods 65 (2014), 18–27.
17. [17] Melis, J.P.M., et al. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol. Immunol. 67 (2015), 117–130.
18. [18] Mamidi, S., Hone, S., Kirschfink, M., The complement system in cancer: ambivalence between tumour destruction and promotion. Immunobiology, 2015.
19. [19] Okada, H., Baba, T., Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane. Nature 248 (1974), 521–522.
20. [20] Irie, K., Irie, R.F., Morton, D.L., Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science 186 (1974), 454–456.
21. [21] Ross, G.D., et al. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology 42 (1999), 61–74.
22. [22] Sokoloff, M.H., et al. Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunol. Immunother. 49 (2000), 551–562.
23. [23] Reff, M.E., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994), 435–445.
24. [24] Maloney, D.G., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997), 2188–2195.
25. [25] Hale, G., The CD52 antigen and development of CAMPATH antibodies. Cytotherapy 3 (2001), 137–143.
26. [26] Teeling, J.L., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 104 (2004), 1793–1800.
27. [27] Lindorfer, M.A., Bakker, J.M., Parren, P.W.H.I., Taylor, R.P., Ofatumumab (Arzerra): A Next-generation Human Therapeutic CD20 Antibody with Potent Complement-dependent Cyt0toxicity. Dubel, S., Reichert, J.M., (eds.) Handbook of therapeutic antibodies, 2014, Wiley Blackwell Weinheim, 1733–1774.
28. [28] Owen, C.J., Stewart, D.A., Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther. Adv. Hematol. 6 (2015), 161–170.
29. [29] Illidge, T., et al. Obinutuzumab in hematologic malignancies: lessons learned to date. Canc. Treat. Rev., 2015.
30. [30] Golay, J., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 95 (2000), 3900–3908.
31. [31] Golay, J., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001), 3383–3389.
32. [32] Di Gaetano, N., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003), 1581–1587.
33. [33] Bologna, L., et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J. Immunol. 190 (2013), 231–239.
34. [34] van Meerten, T., et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12 (2006), 4027–4035.
35. [35] Manches, O., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood 101 (2003), 949–954.
36. [36] Beurskens, F.J., et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 188 (2012), 3532–3541.
37. [37] Baig, N.A., et al. Induced resistance to ofatumumab-mediated cell clearance mechanisms including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J. Immunol. 192 (2014), 1620–1629.
38. [38] de Weers, M., et al. Daratumumab a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186 (2011), 1840–1848.
39. [39] Lokhorst, H.M., et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. New Engl. J. Med. 373 (2015), 1207–1219.
40. [40] Nijhof, I., et al. Expression levels of CD38 and complement inhibitory proteins CD55 and CD59 predict response ot daratumumab in multiple myeloma. Haematologica 100 (2015), 175–176.
41. [41] Phipps, C., et al. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther. Adv. Hematol. 6 (2015), 120–127.
42. [42] Clynes, R.A., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000), 443–446.
43. [43] Kennedy, A.D., et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by Rituximab. Blood 101 (2003), 1071–1079.
44. [44] Zent, C.S., et al. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk. Res. 28 (2004), 495–507.
45. [45] Golay, J., et al. Effect of alemtuzumab on neoplastic B cells. Haematologica 89 (2004), 1476–1483.
46. [46] Glennie, M.J., et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44 (2007), 3823–3837.
47. [47] Zent, C.S., et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stay chronic lymphoctyic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 32 (2008), 1849–1856.
48. [48] Montalvao, F., et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 123 (2013), 5098–5103.
49. [49] Taylor, R.P., Lindorfer, M.A., Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol. Pharm. 86 (2014), 485–491.
50. [50] Boross, P., et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96 (2011), 1822–1830.
51. [51] Kennedy, A.D., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172 (2004), 3280–3288.
52. [52] Hughes-Jones, N.C., The Classical Pathway. Ross, G.D., (eds.) Immunobiology of the complement system, 1986, Academic Press Orlando, 21–44.
53. [53] Pokrass, M.J., et al. Activation of complement by monoclonal antibodies that target cell-associated β2-microglobulin: implications for cancer immunotherapy. Mol. Immunol. 56 (2013), 549–560.
54. [54] Bindon, C.I., Hale, G., Waldmann, H., Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur. J. Immunol. 18 (1988), 1507–1514.
55. [55] Ambrose, L.R., Morel, A.-S., Warrens, A.N., Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 114 (2009), 3052–3055.
56. [56] Beum, P.V., et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181 (2008), 822–832.
57. [57] Beum, P.V., et al. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca2+ influx and induces streamers. Eur. J. Immunol. 41 (2011), 2436–2446.
58. [58] Diebolder, C.A., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343 (2014), 1260–1263.
59. [59] de Jong, R.N., et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol., 14, 2015, e1001244.
60. [60] Mamidi, S., et al. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol. Oncol. 7 (2013), 580–594.
61. [61] Cinci, M., et al. Targeted delivery of siRNA using transferrin-conjugated lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack. Targeted Oncol. 10 (2015), 405–413.
62. [62] Terui, Y., et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci. 97 (2006), 72–79.
63. [63] Geis, N., et al. Inhibition of membrane complement inhibitor expression (CD46, CD55CD59) by siRNA snesitizes tumor cells to complement attack in vitro. Curr. Cancer Drug Targets 10 (2010), 922–931.
64. [64] Zell, S., et al. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol. 150 (2007), 576–584.
65. [65] Zhao, W.P., et al. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol. Rep. 21 (2009), 1405–1411.
66. [66] Ge, X., et al. rILYd4 a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin. Canc. Res. 17 (2011), 6702–6711.
67. [67] Hu, W., et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Canc. Res. 71 (2011), 2298–2307.
68. [68] Lindorfer, M.A., Beum, P.V., Taylor, R.P., CD20 mAb-mediated complement dependent cytotoxicity of tumor cells is enhanced by blocking the action of factor I. Antibodies 2 (2013), 598–616.
69. [69] Horl, S., et al. Complement factor H-derived short consensus repeat 18–20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica 98 (2013), 1939–1947.
70. [70] Horl, S., et al. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 27 (2013), 2200–2208.
71. [71] Derer, S., et al. A complement-optimized EGFR antibody improves cytoxic functions of polymorphonuclear cells against tumor cells. J. Immunol. 195 (2015), 5077–5087.
72. [72] Macor, P., et al. Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia 29 (2015), 406–414.
73. [73] Elvington, M., et al. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 119 (2012), 6043–6051.
74. [74] Dechant, M., et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 68 (2008), 4998–5003.
75. [75] Klausz, K., et al. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci. 102 (2011), 1761–1768.
76. [76] Klitgaard, J.L., et al. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br. J. Hematol. 163 (2013), 182–193.
77. [77] Klepfish, A., et al. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukemia. Lancet Oncol. 8 (2007), 361–362.
78. [78] Xu, W., et al. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int. J. Canc. 128 (2011), 2192–2201.
79. [79] Tempescul, A., et al. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukemia is affected by C4 complement exhaustion. Eur. J. Haematol., 2015.
80. [80] Middleton, O., et al. Complement deficiences limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 29 (2015), 107–114.
81. [81] Lindorfer, M.A., et al. Monoclonal antibody (mAb)-based cancer therapy: is it time to reevaluate dosing strategies?. Oncoimmunology 1 (2012), 959–961.
82. [82] Aue, G., et al. Fractionated subcutaneous rituximab is well tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 95 (2010), 329–332.
83. [83] Baig, N.A., et al. Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement. Leuk. Lymph. 53 (2012), 2218–2227.
84. [84] Zent, C.S., et al. Chemoimmunotherapy for relapsed/refractory and progressive 17p13 deleted chronic lymphocytic leukemia (CLL) combining pentostatin alemtuzumab, and low Dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am. J. Hematol. 89 (2014), 757–765.
85. [85] Schreiber, A.D., Frank, M.M., Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J. Clin. Invest. 51 (1972), 583–589.
86. [86] Schreiber, A.D., Frank, M.M., Role of antibody and complement in the immune clearance and destruction of erythrocytes: i. In vivo effects of IgG and IgM complement fixing sites. J. Clin. Invest. 51 (1972), 575–582.
87. [87] Lindorfer, M.A., Kohl, J., Taylor, R.P., Interactions Between the Complement System and Fcγ Receptors. Ackerman, M.E., Nimmerjahn, F., (eds.) Antibody Fc: Linking Adaptive and Innate Immunity, 2014, Elsevier, Philadelphia, PA, 49–74.
88. [88] Heller, T., et al. Cutting Edge: fc receptor Type I for IgG macrophages and complement mediate the inflammatory response in immune complex peritonitis. J. Immunol. 162 (1999), 5657–5661.
89. [89] Schmidt, R.E., Gessner, J.E., Fc receptors and their interaction with complement in autoimmunity. Immunol. Lett. 100 (2005), 56–67.
90. [90] Wang, S.Y., et al. NK cell activation and antibody dependent cellular cytotoxicity induced by Rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111 (2008), 1456–1463.
91. [91] Kern, D.J., et al. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk. Lymph., 2013.
92. [92] Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15 (2015), 361–370.
93. [93] Veermani, S., et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118 (2011), 3347–3349.
94. [94] Okroj, M., et al. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence. Cancer Immunol. Immunother. 64 (2015), 467–478.
95. [95] Corrales, L.A.D., et al. Anaphylatoxin C5a creates a favorable microenviornment for lung cancer progression. J. Immunol. 189 (2012), 4674–4683.
96. [96] Markiewski, M.M., et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9 (2008), 1225–1235.
97. [97] Moghimi, S.M., Andersen, T.L., Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines. Mol. Immunol. 46 (2009), 1571–1572.
98. [98] Pio, R., Corrales, L., Lambris, J.D., The role of complement in tumor growth. Adv. Exptl. Med. Biol. 772 (2014), 229–262.
99. [99] Rutkowski, M.J., et al. Cancer and the complement cascade. Mol. Canc. Res. 8 (2010), 1453–1465.
100. [100] Bouwens, T.A.M., et al. Complement activation in Glioblastoma Multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. J. Neuroimmunol. 278 (2015), 271–276.
101. [101] Beum, P.V., et al. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. J. Immunol. Methods 317 (2006), 90–99.
102. [102] Teeling, J.L., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177 (2006), 362–371.
103. [103] Williams, M.E., et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 177 (2006), 7435–7443.
104. [104] Dyer, M.J.S., et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73 (1989), 1431–1439.
105. [105] Lindorfer, M.A., et al. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. Mol. Immunol. 70 (2016), 13–23.
106. [106] van Meerten, T., et al. HuMab-7D8 a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20, can effectively eliminate CD20 low expressing tumor cells that resist rituximab mediated lysis. Haematologica 95 (2010), 2063–2071.
107. [107] Pawluczkowycz, A.W., et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183 (2009), 749–758.
108. [108] Bindon, C.I., et al. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 168 (1988), 127–142.
109. [109] Schanne, F.A.X., et al. Calcium dependence of toxic cell death: a final common pathway. Science 206 (1979), 700–702.
110. [110] Gramer, M.J., et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. mAbs 55 (2013), 962–973.
111. [111] Labrijn, A.F., et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 5145–5150.
112. [112] Macor, P., et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 67 (2007), 10556–10563.
113. [113] Hu, W., et al. Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat. Med. 14 (2008), 98–103.
114. [114] Taylor, R.P., Lindorfer, M.A., Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood 125 (2015), 762–766.
115. [115] Zent, C.S., et al. A Phase II randomized trial comparing standard and low Dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN Cancer Research Group (E1908). Am. J. Hematol., 2016.
116. [116] Borsos, T., Rapp, H.J., Complement fixation on cell surfaces by 19S and 7S antibodies. Science 150 (1965), 505–506.
117. [117] Saar Ray, M., et al. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity. J. Biol. Chem. 289 (2014), 15014–15022.